School of Chemistry and Physics, University of KwaZulu-Natal, Private Bag X01, Scottsville, Pietermaritzburg 3209, South Africa.
Int J Mol Sci. 2021 Nov 14;22(22):12294. doi: 10.3390/ijms222212294.
The development of nanomaterials with therapeutic and/or diagnostic properties has been an active area of research in biomedical sciences over the past decade. Nanomaterials have been identified as significant medical tools with potential therapeutic and diagnostic capabilities that are practically impossible to accomplish using larger molecules or bulk materials. Fabrication of nanomaterials is the most effective platform to engineer therapeutic agents and delivery systems for the treatment of cancer. This is mostly due to the high selectivity of nanomaterials for cancerous cells, which is attributable to the porous morphology of tumour cells which allows nanomaterials to accumulate more in tumour cells more than in normal cells. Nanomaterials can be used as potential drug delivery systems since they exist in similar scale as proteins. The unique properties of nanomaterials have drawn a lot of interest from researchers in search of new chemotherapeutic treatment for cancer. Metal sulfide nanomaterials have emerged as the most used frameworks in the past decade, but they tend to aggregate because of their high surface energy which triggers the thermodynamically favoured interaction. Stabilizing agents such as polymer and microgels have been utilized to inhibit the particles from any aggregations. In this review, we explore the development of metal sulfide polymer/microgel nanocomposites as therapeutic agents against cancerous cells.
在过去的十年中，具有治疗和/或诊断特性的纳米材料的发展一直是生物医学科学的一个活跃研究领域。纳米材料已被确定为具有重大医疗意义的工具，具有潜在的治疗和诊断能力，而使用较大的分子或块状材料几乎不可能实现这些能力。纳米材料的制造是工程治疗剂和药物输送系统的最有效平台，用于治疗癌症。这主要是由于纳米材料对癌细胞的高选择性，这归因于肿瘤细胞的多孔形态，允许纳米材料在肿瘤细胞中积累比正常细胞更多。纳米材料可以用作潜在的药物输送系统，因为它们的大小与蛋白质相似。纳米材料的独特性质引起了研究人员的极大兴趣，他们正在寻找治疗癌症的新化疗方法。金属硫化物纳米材料在过去十年中已成为使用最广泛的框架，但由于其高表面能引发热力学有利的相互作用，它们往往会聚集。聚合物和微凝胶等稳定剂已被用于抑制颗粒的任何聚集。在这篇综述中，我们探讨了将金属硫化物聚合物/微凝胶纳米复合材料作为治疗癌症细胞的治疗剂的发展。
